Holen Sie sich die Stockscreener-App
85.12
1.30%
1.09
Vorhandelsmarkt:
85.94
0.82
+0.96%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$84.03
Offen:
$84.49
24-Stunden-Volumen:
1.97M
Relative Volume:
0.56
Marktkapitalisierung:
$33.38B
Einnahmen:
$4.15B
Nettoeinkommen (Verlust:
$535.20M
KGV:
63.52
EPS:
1.34
Netto-Cashflow:
$575.20M
1W Leistung:
+0.40%
1M Leistung:
+6.40%
6M Leistung:
-2.26%
1J Leistung:
-23.76%
1-Tages-Spanne:
$84.25
$85.65
1-Wochen-Bereich:
$83.23
$85.90
52-Wochen-Spanne:
$57.52
$113.28
Dexcom Inc Stock (DXCM) Company Profile
Firmenname
Dexcom Inc
Sektor
Branche
Telefon
(858) 200-0200
Adresse
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Vergleichen Sie DXCM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
85.12 | 33.24B | 4.15B | 535.20M | 575.20M | 1.34 |
|
ABT
Abbott Laboratories
|
125.73 | 228.77B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.16 | 153.09B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
395.15 | 149.27B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
91.65 | 114.31B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.30 | 45.06B | 5.54B | 4.18B | 623.10M | 7.00 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-03 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-03-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2023-01-26 | Eingeleitet | Wolfe Research | Outperform |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-15 | Eingeleitet | Bernstein | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-28 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-01-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-02 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Bestätigt | Piper Sandler | Overweight |
| 2020-05-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-11-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-10-23 | Eingeleitet | Stifel | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-09-12 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Bestätigt | Canaccord Genuity | Buy |
| 2018-07-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
| 2018-05-03 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-04 | Eingeleitet | Goldman | Sell |
| 2018-04-04 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
DexCom Inc. Stock Analysis and ForecastFree Popular Stock Recommendations - jammulinksnews.com
What drives DexCom Inc. stock priceExtraordinary market timing - Autocar Professional
What analysts say about DexCom Inc. stockHigh-yield portfolio picks - jammulinksnews.com
Is DexCom Inc. a good long term investmentUnmatched profit growth - jammulinksnews.com
We Think DexCom (NASDAQ:DXCM) Can Manage Its Debt With Ease - simplywall.st
DexCom: Delivering Consistent Growth (NASDAQ:DXCM) - Seeking Alpha
Still Too Pricey? Dexcom’s Double-Digit Growth May Not Be Enough (DXCM) - Seeking Alpha
Are Medical Stocks Lagging DexCom (DXCM) This Year? - Yahoo Finance
Why This Beaten-Down Medical Device Stock Could Be Your Best Investment for the Next 5 Years - AOL.com
Dexcom recalls 19 models of glucose monitoring receivers - Modern Healthcare
Dexcom’s Recall of Certain CGM Receivers is Class I - Medical Product Outsourcing
Foletta sells Dexcom (DXCM) shares worth $234,216 - Investing.com Australia
Foletta sells Dexcom (DXCM) shares worth $234,216 By Investing.com - Investing.com Canada
FDA updates recall of certain Dexcom CGM speakers (DXCM) - Seeking Alpha
Assessing the Impact of Dexcom's Critical Device Recall on Its Market Position and Investor Sentiment - AInvest
Dexcom recalls glucose monitor receivers due to alert failure risk - Investing.com
Dexcom recalls glucose monitor receivers due to alert failure risk By Investing.com - Investing.com UK
Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews - Cadillac News
DexCom (DXCM) Target Price Raised by Mizuho Analyst | DXCM Stock News - GuruFocus
Analyst recommendations: Airbnb, Dexcom, Gitlab, AMD, Citigroup… - MarketScreener
Morgan Stanley Adjusts DexCom Price Target to $89 From $82, Maintains Equal Weight Rating - MarketScreener
Beyond The Numbers: 8 Analysts Discuss DexCom Stock - Benzinga
DexCom (DXCM) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
When Should You Buy DexCom, Inc. (NASDAQ:DXCM)? - 富途牛牛
How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetes - Benzinga
DexCom, Inc. (DXCM) Stock Analysis: Evaluating a 18.25% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Ravens’ Mark Andrews leads first Dexcom U Signing Day Camp, inspiring young athletes with diabetes - WMAR 2 News Baltimore
Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders - GlobeNewswire
DexCom Is Doubling Down on Its ‘Mistake.’ Why It’s Time to Buy the Stock. - Barron's
Dexcom Unveils Portrait Gallery to Portray Emotional Highs and Lows of Living With Diabetes on World Diabetes Day - Investegate
What You Need to Know Ahead of DexCom’s Earnings Release - MSN
What You Need To Know Ahead Of DexCom’s Earnings Release - Barchart.com
Oppenheimer Reaffirms DexCom Buy Rating Amid HHS Wearables Push - MSN
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year? - Nasdaq
3 Reasons Growth Investors Will Love DexCom (DXCM) - Yahoo Finance
Dexcom Schedules Second Quarter 2025 Earnings Release and Conference Call for July 30, 2025 at 4:30 p.m. Eastern Time. - BioSpace
DexCom (DXCM) Leads Healthcare Sector Gains - GuruFocus
Finanzdaten der Dexcom Inc-Aktie (DXCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.14%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):